Evidence map›Paper›PMID 39661658›Full record

ArticlePLoS pathogens2024

Viral microRNA regulation of Akt is necessary for reactivation of Human Cytomegalovirus from latency in CD34+ hematopoietic progenitor cells and humanized mice.

Nicole L Diggins, Andrew H Pham, Jennifer Mitchell, Christopher J Parkins, Luke Slind, Rebekah Turner, Byeong-Jae Lee, Andrew D Yurochko, Patrizia Caposio, Jay A Nelson and 1 more

Abstract read
In one paragraph

Article in PLoS pathogens, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Nicole L DigginsVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Andrew H PhamVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Jennifer MitchellVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Christopher J ParkinsVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Luke SlindVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Rebekah TurnerVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Byeong-Jae LeeDepartment of Microbiology & Immunology, Center for Applied Immunology and Pathological Processes, Center for Emerging Viral Threats, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States of America.
Andrew D YurochkoDepartment of Microbiology & Immunology, Center for Applied Immunology and Pathological Processes, Center for Emerging Viral Threats, Louisiana State University Health Sciences Center-Shreveport, Shreveport, Louisiana, United States of America.
Patrizia CaposioVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Jay A NelsonVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.
Meaghan H HancockVaccine and Gene Therapy Institute, Oregon Health & Science University, Beaverton, Oregon, United States of America.ORCID 0000-0003-2945-0147

Funding

Upgrade of confocal microscopy at the Oregon National Primate Research CenterP51OD011092 · OD · OREGON HEALTH & SCIENCE UNIVERSITY · PI Bonnie J. Nagel · 2012 to 2026
$203.9M
Project 4-Tracking cytomegalovirus-primed long-lived NK cells in salivary glandP20GM134974 · NIGMS · LOUISIANA STATE UNIV HSC SHREVEPORT · PI ANDREW D YUROCHKO · 2021 to 2026
$15.0M
MOLECULAR ASPECTS OF CYTOMEGALOVIRUS LATENCYR01AI021640 · NIAID · UNIVERSITY OF GUELPH · PI Meaghan H Hancock · 1985 to 2026
$8.1M
NIAID NIH HHS R01 AI021640NIGMS NIH HHS P20 GM134974NIH HHS P51 OD011092
6 · The paper itself

Abstract

Human cytomegalovirus (HCMV) actively manipulates cellular signaling pathways to benefit viral replication. Phosphatidyl-inositol 3-kinase (PI3K)/Akt signaling is an important negative regulator of HCMV replication, and during lytic infection the virus utilizes pUL38 to limit Akt phosphorylation and activity. During latency, PI3K/Akt signaling also limits virus replication, but how this is overcome at the time of reactivation is unknown. Virally encoded microRNAs (miRNAs) are a key component of the virus arsenal used to alter signaling during latency and reactivation. In the present study we show that three HCMV miRNAs (miR-UL36, miR-UL112 and miR-UL148D) downregulate Akt expression and attenuate downstream signaling, resulting in the activation of FOXO3a and enhanced internal promoter-driven IE transcription. A virus lacking expression of all three miRNAs is unable to reactivate from latency both in CD34+ hematopoietic progenitor cells and in a humanized mouse model of HCMV infection, however downregulating Akt restores the ability of the mutant virus to replicate. These findings highlight the negative role Akt signaling plays in HCMV replication in lytic and latent infection and how the virus has evolved miRNA-mediated countermeasures to promote successful reactivation.

Indexed as

CytomegalovirusCytomegalovirus InfectionsHematopoietic Stem CellsMicroRNAsProto-Oncogene Proteins c-aktVirus ActivationVirus LatencyAnimalsAntigens, CD34Gene Expression Regulation, ViralHumansMiceRNA, ViralSignal TransductionVirus ReplicationAntigens, CD34MicroRNAsProto-Oncogene Proteins c-aktRNA, Viral

Identifiers

PMID39661658
PMCPMC11666035

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.